Literature DB >> 28831534

Comparison of 18F-FET PET and perfusion-weighted MRI for glioma grading: a hybrid PET/MR study.

Antoine Verger1,2,3, Christian P Filss1,4, Philipp Lohmann1, Gabriele Stoffels1, Michael Sabel5, Hans J Wittsack6, Elena Rota Kops1, Norbert Galldiks1,7,8, Gereon R Fink1,7,8, Nadim J Shah1,9,10, Karl-Josef Langen11,12,13.   

Abstract

PURPOSE: Both perfusion-weighted MR imaging (PWI) and O-(2-18F-fluoroethyl)-L-tyrosine PET (18F-FET) provide grading information in cerebral gliomas. The aim of this study was to compare the diagnostic value of 18F-FET PET and PWI for tumor grading in a series of patients with newly diagnosed, untreated gliomas using an integrated PET/MR scanner.
METHODS: Seventy-two patients with untreated gliomas [22 low-grade gliomas (LGG), and 50 high-grade gliomas (HGG)] were investigated with 18F-FET PET and PWI using a hybrid PET/MR scanner. After visual inspection of PET and PWI maps (rCBV, rCBF, MTT), volumes of interest (VOIs) with a diameter of 16 mm were centered upon the maximum of abnormality in the tumor area in each modality and the contralateral unaffected hemisphere. Mean and maximum tumor-to-brain ratios (TBRmean, TBRmax) were calculated. In addition, Time-to-Peak (TTP) and slopes of time-activity curves were calculated for 18F-FET PET. Diagnostic accuracies of 18F-FET PET and PWI for differentiating low-grade glioma (LGG) from high-grade glioma (HGG) were evaluated by receiver operating characteristic analyses (area under the curve; AUC).
RESULTS: The diagnostic accuracy of 18F-FET PET and PWI to discriminate LGG from HGG was similar with highest AUC values for TBRmean and TBRmax of 18F-FET PET uptake (0.80, 0.83) and for TBRmean and TBRmax of rCBV (0.80, 0.81). In case of increased signal in the tumor area with both methods (n = 32), local hot-spots were incongruent in 25 patients (78%) with a mean distance of 10.6 ± 9.5 mm. Dynamic FET PET and combination of different parameters did not further improve diagnostic accuracy.
CONCLUSIONS: Both 18F-FET PET and PWI discriminate LGG from HGG with similar diagnostic performance. Regional abnormalities in the tumor area are usually not congruent indicating that tumor grading by 18F-FET PET and PWI is based on different pathophysiological phenomena.

Entities:  

Keywords:  Fet pet; Glioma; Grading; PET/MR imaging; Pwi

Mesh:

Substances:

Year:  2017        PMID: 28831534     DOI: 10.1007/s00259-017-3812-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  49 in total

1.  [User friendly analysis of MR investigations of the cerebral perfusion: Windows(R)-based image processing].

Authors:  H J Wittsack; A Ritzl; U Mödder
Journal:  Rofo       Date:  2002-06

2.  Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?

Authors:  Matthew L White; Yan Zhang; Patricia Kirby; Timothy C Ryken
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

3.  Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma.

Authors:  Stephan Ulmer; Carsten Liess; Santosh Kesari; Nadine Otto; Torsten Straube; Olav Jansen
Journal:  J Neurooncol       Date:  2008-09-21       Impact factor: 4.130

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading.

Authors:  Gabriele Pöpperl; Friedrich W Kreth; Jan H Mehrkens; Jochen Herms; Klaus Seelos; Walter Koch; Franz J Gildehaus; Hans A Kretzschmar; Jörg C Tonn; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-01       Impact factor: 9.236

6.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Authors:  Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin
Journal:  Neuro Oncol       Date:  2014-01-15       Impact factor: 12.300

7.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

Review 8.  Metabolic and molecular imaging in neuro-oncology.

Authors:  Karl Herholz; David Coope; Alan Jackson
Journal:  Lancet Neurol       Date:  2007-08       Impact factor: 44.182

Review 9.  The role of diffusion and perfusion weighted imaging in the differential diagnosis of cerebral tumors: a review and future perspectives.

Authors:  Patricia Svolos; Evanthia Kousi; Eftychia Kapsalaki; Kyriaki Theodorou; Ioannis Fezoulidis; Constantin Kappas; Ioannis Tsougos
Journal:  Cancer Imaging       Date:  2014-04-29       Impact factor: 3.909

Review 10.  The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy.

Authors:  Norbert Galldiks; Ian Law; Whitney B Pope; Javier Arbizu; Karl-Josef Langen
Journal:  Neuroimage Clin       Date:  2016-12-18       Impact factor: 4.881

View more
  18 in total

1.  Summary of the First ISMRM-SNMMI Workshop on PET/MRI: Applications and Limitations.

Authors:  Thomas A Hope; Zahi A Fayad; Kathryn J Fowler; Dawn Holley; Andrei Iagaru; Alan B McMillan; Patrick Veit-Haiback; Robert J Witte; Greg Zaharchuk; Ciprian Catana
Journal:  J Nucl Med       Date:  2019-05-23       Impact factor: 10.057

2.  Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models.

Authors:  Benjamin B Kasten; Ke Jiang; Denzel Cole; Aditi Jani; Neha Udayakumar; G Yancey Gillespie; Guolan Lu; Tingting Dai; Eben L Rosenthal; James M Markert; Jianghong Rao; Jason M Warram
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-26       Impact factor: 9.236

3.  Glioma grading by dynamic susceptibility contrast perfusion and 11C-methionine positron emission tomography using different regions of interest.

Authors:  Cornelia Brendle; Johann-Martin Hempel; Jens Schittenhelm; Marco Skardelly; Gerald Reischl; Benjamin Bender; Ulrike Ernemann; Christian la Fougère; Uwe Klose
Journal:  Neuroradiology       Date:  2018-02-20       Impact factor: 2.804

4.  Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR Fingerprinting.

Authors:  Johannes Haubold; Aydin Demircioglu; Marcel Gratz; Martin Glas; Karsten Wrede; Ulrich Sure; Gerald Antoch; Kathy Keyvani; Mathias Nittka; Stephan Kannengiesser; Vikas Gulani; Mark Griswold; Ken Herrmann; Michael Forsting; Felix Nensa; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-06       Impact factor: 9.236

Review 5.  The Use of 18F-FET-PET-MRI in Neuro-Oncology: The Best of Both Worlds-A Narrative Review.

Authors:  Tineke van de Weijer; Martijn P G Broen; Rik P M Moonen; Ann Hoeben; Monique Anten; Koos Hovinga; Inge Compter; Jochem A J van der Pol; Cristina Mitea; Toine M Lodewick; Arnaud Jacquerie; Felix M Mottaghy; Joachim E Wildberger; Alida A Postma
Journal:  Diagnostics (Basel)       Date:  2022-05-11

6.  Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma.

Authors:  Michael Lundemann; Per Munck Af Rosenschöld; Aida Muhic; Vibeke A Larsen; Hans S Poulsen; Svend-Aage Engelholm; Flemming L Andersen; Andreas Kjær; Henrik B W Larsson; Ian Law; Adam E Hansen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-02       Impact factor: 9.236

7.  Static 18F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status.

Authors:  Shuangshuang Song; Leiming Wang; Hongwei Yang; Yongzhi Shan; Ye Cheng; Lixin Xu; Chengyan Dong; Guoguang Zhao; Jie Lu
Journal:  Eur Radiol       Date:  2020-11-19       Impact factor: 5.315

8.  Exploring diagnostic performance of T2 mapping in diffuse glioma grading.

Authors:  Weibin Gu; Shiyuan Fang; Xinyi Hou; Ding Ma; Shaowu Li
Journal:  Quant Imaging Med Surg       Date:  2021-07

9.  The Utility of Diffusion and Perfusion Magnetic Resonance Imaging in Target Delineation of High-Grade Gliomas.

Authors:  Qian Fei; Lu-Xi Qian; Yu-Jie Zhang; Wen-Jie Guo; Xiu-Hua Bian; Li Yin; Peng-Wei Yan; Ting-Ting Wang; Pu-Dong Qian; Zhen Guo; Xia He
Journal:  Biomed Res Int       Date:  2020-08-10       Impact factor: 3.411

10.  Voxel-wise analysis of dynamic 18F-FET PET: a novel approach for non-invasive glioma characterisation.

Authors:  Lena Vomacka; Marcus Unterrainer; Adrien Holzgreve; Erik Mille; Astrid Gosewisch; Julia Brosch; Sibylle Ziegler; Bogdana Suchorska; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn; Peter Bartenstein; Nathalie Lisa Albert; Guido Böning
Journal:  EJNMMI Res       Date:  2018-09-10       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.